Ovarian cancer screening.

Mackey, Sue; Creasman, William T.

doi:10.1200/jco.1995.13.3.783

Cited by 31 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although a number of tumour markers have been identified (Bast et al, 1987;Berek and Bast, 1995;Mackey and Creasman, 1995;Chen and Karlan, 1998), a useful screening marker for ovarian cancer has not yet been clearly established. The most widely used marker, CA125, has shown merit in pilot screening studies and ovarian cancer management, but the sensitivity for early-stage disease before clinical detection remains questionable (Bast et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

Characterisation of human kallikrein 6/protease M expression in ovarian cancer

Zhang

Huang

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Kallikrein 6 (hK6, also known as protease M/zyme/neurosin) is a member of the human kallikrein gene family. We have previously cloned the cDNA for this gene by differential display and shown the overexpression of the mRNA in breast and ovarian primary tumour tissues and cell lines. To thoroughly characterise the expression of this kallikrein in ovarian cancer, we have developed a novel monoclonal antibody specific to hK6 and employed it in immunohistochemistry with a wide range of ovarian tumour samples. The expression was found elevated in 67 of 80 cases of ovarian tumour samples and there was a significant difference in the expression levels between normal and benign ovarian tissues and the borderline and invasive tumours (Po0.001). There was no difference of expression level between different subtypes of tumours. More significantly, high level of kallikrein 6 expression was found in many early-stage and low-grade tumours, and elevated hK6 proteins were found in benign epithelia coexisting with borderline and invasive tissues, suggesting that overexpression of hK6 is an early phenomenon in the development of ovarian cancer. Quantitative real-time reverse transcription -polymerase chain reactions also showed elevated kallikrein 6 mRNA expression in ovarian tumours. Genomic Southern analysis of 19 ovarian tumour samples suggested that gene amplification is one mechanism for the overexpression of hK6 in ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterisation of human kallikrein 6/protease M expression in ovarian cancer

Zhang

Huang

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In ovarian tumors, the downregulation of OVCA1 and OVCA2 (tumor suppressor genes present in normal ovary) is reported, while their functions in normal ovary are not well known [11,16]. In contrast, overexpression/amplification of certain oncogenes like C-MYC, RAS, AKT, EGFR (ErbB1 or HER1), HER2/neu (ErbB2), CSF1 C-MYC, etc., is also well known in ovarian tumors [3-5,11,14,17-20]. …”

Section: Ovarian Cancermentioning

confidence: 99%

Mucins in ovarian cancer diagnosis and therapy

2009

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecologic malignancy and the five-year survival rate is only 35% after diagnosis. Epithelial ovarian cancer is a highly metastatic disease characterized by widespread peritoneal dissemination and ascites. The death incidences from ovarian cancer could be significantly lowered by developing new methods for the early diagnosis and treatment of this fatal disease. Several potential markers have been identified recently. However, mucins are the most promising markers for ovarian cancer diagnosis. Mucins are large extracellular, heavily glycosylated proteins and their aberrant expression has been implicated in the pathogenesis of a variety of cancers, including ovarian cancer. This review will summarize known facts about the pathological and molecular characteristics of ovarian cancer, the current status of ovarian cancer markers, as well as general information about mucins, the putative role of mucins in the progression of ovarian cancer and their potential use for the early diagnosis and treatment of this disease.

show abstract

“…None of these methods alone achieves the required level of sensitivity. For example, CA 125 measurement detects only about 50% of stage 1 ovarian tumours 28. In the general population, clinical examination, transabdominal29 and transvaginal 30 31 ultrasonography, and serum CA 125 screening tests,32 either alone or in combination,33 have been assessed as potential screening tests in various settings.…”

Section: Feasibility Of Early Diagnosis or Preventionmentioning

confidence: 99%